In a campaign to significantly reduce the most common cancer affecting Mexican women, the Mexican Public Health Agency has announced it is launching the first phase of a program that will offer testing for human papillomavirus , the primary cause of cervical cancer, to low-income women age 35-65.
Among the earnings projection stories for Tuesday, Nov. 11, from AP Financial News: HARTFORD, Conn. -- Diversified manufacturer Tyco International Ltd. said Tuesday that per-share profit for 2009 will fall short of Wall Street estimates.
Among the earnings stories for Tuesday, Nov. 11, from AP Financial News: Syneron Medical Ltd. said Tuesday profit plummeted 73 percent in the third quarter as fewer physicians invested in the company's skin treatment devices, sending shares lower.
Netherlands-based diagnostic products maker Qiagen NV said late Monday it is raising full-year profit guidance following a swing to a third-quarter profit from a year-earlier loss.
Netherlands-based diagnostic products maker Qiagen NV said late Monday it swung to a third-quarter profit on higher sales of molecular and other diagnostic products.
VENLO, The Netherlands, Nov. 10, 2008 -- QIAGEN N.V. today announced the results of operations for the third quarter and the nine-month period ended September 30, 2008.
BEDFORD, Mass. (AP) - Diagnostic test maker Hologic Inc. late Thursday said its Cervista HPV test met or exceeded expectations in a trial of more than 4,000 women.
NEW YORK (AP) - Netherlands-based diagnostic products maker Qiagen NV said late Monday it is raising full-year profit guidance following a swing to a third-quarter profit from a year-earlier loss.
NEW YORK (AP) - Netherlands-based diagnostic products maker Qiagen NV said late Monday it swung to a third-quarter profit on higher sales of molecular and other diagnostic products.
QIAGEN N.V. (NASDAQ: QGEN)(FRANKFURT: QIA) today announced the launch of anew test to determine mutations of the K-ras gene. The K-ras gene ismutated in between 35 percent and 45 percent of metastatic colorectalcancer (CRC) patients. Studies have shown that K-ras testing canbetter define which CRC patients will benefit from treatment withepidermal growth factor receptor (EGFR) inhibiting monoclonalantibodies, such as Amgen's Vectibix® (panitumumab) andImclone/Bristol-Myers Squibb's Erbitux® (cetuximab).
Stories about new deals, drug development and financial news showed that China biophama continued its evolution last week. Phynova (PHNVY.PK) was a prominent example. The UK-based botanical drug company announced that it has adopted a more China-centric focus (see story). Traditionally, the company has always had a connection to China; it owns a 45% share in Botanic Century Beijing Ltd, a drug development company, and its previous business plan called for the use of TCM formulations as a basis for drugs that addressed unmet...
The Dutch diagnostics company Qiagen (QGEN) will collaborate with the Chinese Academy of Sciences [CAS] to develop new molecular tests that will determine the safety of food.
The collaboration will be housed in the Institute of Nutritional Sciences [INS], Shanghai Institute of Biological Sciences [SIBS] in the Xuhui district. Qiagen will equip the collaboration with instruments and consumables while CAS will provide the physical space and researchers.
QIAGEN (QGEN)
established a Service Solutions Center in Singapore that will serve the
Asia-Pacific region. The new facility brings to seven the number of
Service Solutions centers throughout the world: Valencia, CA and
Germantown, MD in the US; Hilden, Crawley and Paris in Europe; and
Tokyo in Japan.
The company says that its support network will be able, by the end of
2008, to provide a comprehensive set of services at any time in any
place in the world. The round-the-clock operation is expected...
Last week witnessed continuing investment in the world of China
biopharma, much of which came from the West. In one initiative, QIAGEN
(QGEN),
the Dutch company that makes lab equipment to test and purify nucleic
acids and proteins, has established an Asia-Pacific Service Solutions
Center (see story).
The latest center, located in Singapore, is the seventh Service
Solutions Center worldwide. By the end of 2008, all the centers will be
open 24 hours per day, seven days per week, making QIAGEN?s products
always available. In December 2007, QIAGEN also opened a molecular
diagnostics R&D...
Investment in China biopharma prospered last week
across a varied front. In a new story, Lilly (LLY)
announced that its initiative called Lilly Asian Ventures has plans to
invest $100 million in up and coming China biopharma over the next
five years. Pointing out that 20% of its researchers are Chinese in
origin, Lilly says the new initiative will take Lilly to the
innovators, rather than asking the innovators to come to them. Earlier
this year, Lilly Asian Ventures made its first investment, putting $10
million with BioVeda China, a venture capital fund...
Qiagen (QGEN),
the Dutch diagnostic testing company, announced that its FastHPV Test,
an affordable test for HPV designed for use in low-resource areas of
the world, passed a clinical trial conducted in China. The trial
enrolled 2,500 women, aged 30 to 54, most of whom live in rural areas
of China. Once finalized, the results from the test will be used to
support a request for market approval of the FastHPV test. The request
will initially be submitted in China and India in 2008.
QIAGEN (QGEN) and Digene (DIGE) announced on Tuesday that the 30 day waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expired on July 16 without any action taken by the United States government to delay the deal.
Antitrust approval is one of the conditions to completing the transaction.
Qiagen, a Dutch manufacturer of genetic testing equipment, announced Sunday it will purchase Digene Corp. for $1.6 billion in cash and stock. Digene produces DNA and RNA screening tests for cervical cancer and other diseases affecting women. Holders of Digene shares will receive cash and shares of Qiagen valuing each Digene share at $61.25, 37% above their Friday close. Qiagen is projecting that Digene will add revenue of $58-60 million in Q4 and $260-270 million for full-year 2008. The combined company is forecast to post molecular diagnostics revenues of over...
Dyax (DYAX) reported its hereditary angioedema drug DX-88 produced positive data in a Phase III trial. DX-88, a recombinant, plasma kallikrein inhibitor, treats acute attacks of HAE, a genetic disease characterized by episodes of swelling and inflammation.
The drug produced a statistically significant reduction in symptom scores in a shorter period of time than placebo. Dyax enjoyed a 49% climb, moving up $1.97 to $5.97.
During 3Q 08, Qiagen NV?s (Qiagen) revenues experienced robust growth, in-line with our estimate. Revenues are expected to be driven by recurring sales of reagents, further augment by wider ...
DJ DGAP-AFR: Qiagen NV: Announcement according to Articles 37v, 37w, 37x et seqq. of the WpHG [the German Securities Act] with the objective of Europe-wide distribution QIAGEN NV / Preliminary ...
In a campaign to significantly reduce the most common cancer affecting Mexican women, the Mexican Public Health Agency (Secretaria de Salud or SSA) has announced it is launching the first phase of ...
In a campaign to significantly reduce the most common cancer affecting Mexican women, the Mexican Public Health Agency (Secretaria de Salud) announced that it is launching the first phase of a ...
MEXICO CITY, Mexico, November 19 /PRNewswire/ -- In a campaign to significantly reduce the most common cancer affecting Mexican women, the Mexican Public Health Agency (Secretaria de Salud or SSA ...
Liège, Belgium - November 12, 2008, 08.00 CET - OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) announced today that it has signed a world-wide, non-exclusive license ...
Registration period for the 2009 IR Global Rankings ends November 14, 2008 NEW YORK, Nov. 13 /PRNewswire/ -- MZ Consult NY (http://www.mz-ir.com), a leading global investor relations and financial ...
QIAGEN's Customers Can Streamline the Procurement Process using SciQuest's Solutions CARY, NC, Nov. 12 /PRNewswire/ -- SciQuest, Inc., the global leader empowering enterprises to realize the ...
AP 11.11.08, 11:15 AM ET Netherlands-based diagnostic products maker Qiagen NV said late Monday it swung to a third-quarter profit on higher sales of molecular and other diagnostic products. The ...
Among the companies whose shares are seeing active trade in Tuesday’s session are the auto makers, Anheuser-Busch, Dollar Thrifty, Fortune Brands, Smithfield Foods and UBS.
TEL AVIV (MarketWatch) -- Qiagen NV, the Venlo, Netherlands, provider of biological sampling and assay technologies, said on Tuesday that it acquired closely held Corbett Life Science Pty. of Sydney. For Corbett, which develops and produces life-sciences instrumentation, Qiagen said it would pay US$66 million cash, $4 million in restricted common stock and as much as US$65 million conditioned on meeting milestones and other criteria over the next four years. The purchase extends Qiagen's molecular-testing-solution portfolio and enhances its offerings of sampling and assay technology, Qiagen said. The company said that it would take a third-quarter charge of 2...
Bracing for a rocky 2008, investors in health-care stocks are increasingly moving their cash out of "one-hit" wonder drug developers and into companies with broader-based product portfolios, according to analysts at Cowen and Co.
NEW YORK (MarketWatch) -- U.S. stocks managed to close higher Monday, after investors took news of another overnight stumble in the Shanghai stock market in stride, and a sustained stream of deal news offset rising bond yields and crude prices.
BOSTON (MarketWatch) -- Shares of Digene Corp. soared on Monday, rallying in response to Dutch rival Qiagen NV's move to acquire the molecular-diagnostics company for $1.6 billion in cash and stock.
LONDON (MarketWatch) -- U.S. stock futures on Monday were lower amid the increasing attractiveness of government bonds as well as another precipitous drop in Shanghai-listed stocks overnight.
SAN FRANCISCO (MarketWatch) -- Medical diagnostics firm Digene Corp. has reached a deal to be acquired by Dutch biotech Qiagen NV in a cash-and-stock deal valued at $1.6 billion, the companies announced Sunday.
SAN FRANCISCO (MarketWatch) -- Qiagen NV said after Wednesday's closing bell that it has extended a distribution agreement with Abbott Laboratories for Qiagen's RealArt molecular diagnostic tests. Terms weren't disclosed. Abbott also has non-exclusive distribution rights to certain Qiagen products, including infectious disease tests for hepatitis B virus and Epstein-Barr virus.
Stocks 
The new facility brings to seven the number of
Service Solutions centers throughout the world: Valencia, CA and
Germantown, MD in the US; Hilden, Crawley and Paris in Europe; and
Tokyo in Japan. 
